GMN: Georgian Medical News is peer-reviewed, published monthly journal committed to promoting the science and art of medicine and the betterment of public health, published by the GMN Editorial Board since 1994. GMN carries original scientific articles on medicine, biology and pharmacy, which are of experimental, theoretical and practical character; publishes original research, reviews, commentaries, editorials, essays, medical news, and correspondence in English and Russian.

GMN is indexed in MEDLINE, SCOPUS, PubMed and VINITI Russian Academy of Sciences. The full text content is available through EBSCO databases.

GEORGIAN MEDICAL NEWS

WEBSITE
www.geomednews.com
К СВЕДЕНИЮ АВТОРОВ!

При направлении статьи в редакцию необходимо соблюдать следующие правила:

1. Статья должна быть представлена в двух экземплярах, на русском или английском языках, напечатанная через полтора интервала на одной стороне стандартного листа с шириной левого поля в три сантиметра в три сантиметра. Используемый компьютерный шрифт для текста на русском и английском языках - Times New Roman (Кириллица), для текста на грузинском языке следует использовать AcadNusx. Размер шрифта - 12. К рукописи, напечатанной на компьютере, должен быть приложен CD со статьей.

2. Размер статьи должен быть не менее десяти и не более двадцати страниц машинописи, включая указатель литературы и резюме на английском, русском и грузинском языках.

3. В статье должны быть освещены актуальность данного материала, методы и результаты исследования и их обсуждение.

При представлении в печать научных экспериментальных работ авторы должны указывать вид и количество экспериментальных животных, применяющиеся методы обезболивания и усыпления (в ходе острых опытов).

4. К статье должны быть приложены краткое (на полстраницы) резюме на английском, русском и грузинском языках (включающее следующие разделы: цель исследования, материал и методы, результаты и заключение) и список ключевых слов (key words).

5. Таблицы необходимо представлять в печатной форме. Фотокопии не принимаются. Все цифровые, итоговые и процентные данные в табличках должны соответствовать таковым в тексте статьи. Таблицы и графики должны быть озаглавлены.

6. Фотографии должны быть контрастными, фотокопии с рентгенограмм - в позитивном изображении. Рисунки, чертежи и диаграммы следует озаглавить, пронумеровать и вставить в соответствующее место в tiff формате.

7. Фамилии отечественных авторов приводятся в оригинальной транскрипции.


В конце каждой оригинальной статьи приводится библиографический список. В список литературы включаются все материалы, на которые имеются ссылки в тексте. Список составляется в алфавитном порядке и нумеруется. Литературный источник приводится на языке оригинала. В списке литературы сначала приводятся работы, написанные знаками грузинского алфавита, затем кириллицей и латиницей. Ссылки на цитируемые работы в тексте статьи даются в квадратных скобках в виде номера, соответствующего номеру данной работы в списке литературы. Большинство цитированных источников должны быть за последние 5-7 лет.

9. Для получения права на публикацию статья должна иметь от руководителя работы или учреждения визу и сопроводительное отношение, написанные или напечатанные на бланке и заверенные подписью и печатью.

10. В конце статьи должны быть подписаны все авторы, полностью приведены их фамилии, имена и отчества, указаны служебный и домашний номера телефонов и адреса или иные координаты. Количество авторов (соавторов) не должно превышать пяти человек.

11. Редакция оставляет за собой право сокращать и исправлять статьи. Корректура авторам не высылается, вся работа и сверка проводится по авторскому оригиналу.

12. Недопустимо направление в редакцию работ, представленных к печати в иных издательствах или опубликованных в других изданиях.

При нарушении указанных правил статьи не рассматриваются.
REQUIREMENTS

Please note, materials submitted to the Editorial Office Staff are supposed to meet the following requirements:

1. Articles must be provided with a double copy, in English or Russian languages and typed or computer-printed on a single side of standard typing paper, with the left margin of 3 centimeters width, and 1.5 spacing between the lines, typeface - Times New Roman (Cyrillic), print size - 12 (referring to Georgian and Russian materials). With computer-printed texts please enclose a CD carrying the same file titled with Latin symbols.

2. Size of the article, including index and resume in English, Russian and Georgian languages must be at least 10 pages and not exceed the limit of 20 pages of typed or computer-printed text.

3. Submitted material must include a coverage of a topical subject, research methods, results, and review.

Authors of the scientific-research works must indicate the number of experimental biological species drawn in, list the employed methods of anesthetization and soporific means used during acute tests.

4. Articles must have a short (half page) abstract in English, Russian and Georgian (including the following sections: aim of study, material and methods, results and conclusions) and a list of key words.

5. Tables must be presented in an original typed or computer-printed form, instead of a photocopied version. Numbers, totals, percentile data on the tables must coincide with those in the texts of the articles. Tables and graphs must be headed.

6. Photographs are required to be contrasted and must be submitted with doubles. Please number each photograph with a pencil on its back, indicate author’s name, title of the article (short version), and mark out its top and bottom parts. Drawings must be accurate, drafts and diagrams drawn in India ink (or black ink). Photocopies of the X-ray photographs must be presented in a positive image in tiff format.

Accurately numbered subtitles for each illustration must be listed on a separate sheet of paper. In the subtitles for the microphotographs please indicate the ocular and objective lens magnification power, method of coloring or impregnation of the microscopic sections (preparations).

7. Please indicate last names, first and middle initials of the native authors, present names and initials of the foreign authors in the transcription of the original language, enclose in parenthesis corresponding number under which the author is listed in the reference materials.


In GMN style for each work cited in the text, a bibliographic reference is given, and this is located at the end of the article under the title “References”. All references cited in the text must be listed. The list of references should be arranged alphabetically and then numbered. References are numbered in the text [numbers in square brackets] and in the reference list and numbers are repeated throughout the text as needed. The bibliographic description is given in the language of publication (citations in Georgian script are followed by Cyrillic and Latin).

9. To obtain the rights of publication articles must be accompanied by a visa from the project instructor or the establishment, where the work has been performed, and a reference letter, both written or typed on a special signed form, certified by a stamp or a seal.

10. Articles must be signed by all of the authors at the end, and they must be provided with a list of full names, office and home phone numbers and addresses or other non-office locations where the authors could be reached. The number of the authors (co-authors) must not exceed the limit of 5 people.

11. Editorial Staff reserves the rights to cut down in size and correct the articles. Proof-sheets are not sent out to the authors. The entire editorial and collation work is performed according to the author’s original text.

12. Sending in the works that have already been assigned to the press by other Editorial Staffs or have been printed by other publishers is not permissible.

Articles that Fail to Meet the Aforementioned Requirements are not Assigned to be Reviewed.
სტატიის კომპლექსური სტატიის გარემოგების პროცესი დასრულებულ ქმედის ზედგაით

1. სტატიის ტექსტი დამატებით 2 გალომატო, რომლებიც არ შეიცავენ ენებისადგენელთა სტრუქტურულ ოფერატიულ ეპიზოდებს 1 ოფერატიულ, 3 ოფერატიულ შინაგან ადგილი და სტატიის ძირის 1.5 გამოცდილობის დაცვა. გამოცდილობის კრიტიკული პროცესი ურთიერთად და შეიმჩნევილი ქმედები - Times New Roman (კირილიცა), ხოლო ჯარისწრაფები შეიცავთ საჭირო პარაგრაფში AcadNusx. შინაგანი ბოლო - 12. სტატიის ძირ უნდა შეიცვალო ქმედი CD ჟურნალზე.

2. სტატიის შედეგის ამ უნდა შეაქცეოდე 10 ექნები სითხელზე და 20 ექნები მუქ ლოგოტიპის სითხე და უფროსების (ინგლისურ, რუსულ და ქართულ ოფისი) ზოგადობით.

3. სტატიები ძირითადი გამოქვეყნების საძირკველთან კონტაქტით გადაგზავნა: საქართველო პალატა და ქართულ ფორუმში. ნიუ-იორკში და მაია გამოქვეყნებები; მაია გამოქვეყნება და მაია გამოქვეყნები: საქართველო საქართველო ფორუმის დაახლოება. ქართულ ლანგუაზის სტატიის გამოცდილობის თემაზე: სამოქალახო, რუსულ და ქართულ ფორუმშიან (ქართულ ჟურნალა პარაგრაფები).

GEORGIAN MEDICAL NEWS
No 6 (339) 2023

Tsitsino Abakelia, Ketevan Lashkhi, Sophio Kakhadze.
BRIDGING GAP BETWEEN PRE AND POSTOPERATIVE PROSTATE BIOPSIES: PI RADS CORRELATION WITH FINAL HISTOPATHOLOGICAL DATA.............6-12

Sopio Gvazava, Vladimir Margvelashvili, Nino Chikhladze, Diana Dulfi, Corinne Peek-Asa.
A RETROSPECTIVE STUDY OF THE MAXILLOFACIAL INJURIES IN TWO EMERGENCY DEPARTMENTS IN TBILISI, GEORGIA.................................13-19

EXPENDITURE ON MEDICINES IN A MULTIDISCIPLINARY HOSPITAL IN ALMATY BASED ON ABC /VEN ANALYSIS........20-23

Tchernev G.
NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRISS (PAROXETINE), SNRIS (VENLAFAXINE) AND METFORMIN: THE MOST PROBABLE EXPLANATION FOR THE RISING SKIN CANCER INCIDENCE........24-32

INFLUENCE OF PROFICIENCY OF SYNTHETIC FOLIC ACID ON THE NEUROLOGICAL SYMPTOMS OF RATS......................33-36

Zamzam AR. Aziz, Entedhar R. Sarhat, Zaidan J. Zaidan.
ESTIMATION OF SERUM FERROPORTIN AND LIVER ENZYMES IN BREAST CANCER PATIENTS........................................37-41

Tereza Azatyan.
THE RHEOENCEPHALOGRAPHIC STUDY OF THE INTERHEMISPHERIC ASYMMETRY OF CEREBRAL BLOOD FLOW IN HEALTHY AND MENTALLY RETARDED CHILDREN........................................42-46

Ahmed T. Jihad, Entedhar R. Sarhat.
ALTERED LEVELS OF ANTI-MULLERIAN HORMONE AND HEPcidIN AS POTENTIAL BIOMARKERS FOR POLYCYSTIC OVARY SYNDROME...............................................................47-51

EFFECTS OF DIMETHYL SULFOXIDE ON HIPPOCAMPAL ACTIVITY IN A ROTENONE-INDUCED RAT MODEL OF PARKINSON’S DISEASE.................................................................52-56

Labeeb H. Al-Alsadoon, Ghada A. Taqa, Maha T. Al-Saffar.
EVALUATION OF PAIN-KILLING ACTION OF ACETYLSALICYLIC ACID NANOPARTICLES ON THERMAL NOCICEPTION IN MICE.................................................................57-61

Olesia Kornus, Anatolii Kornus, Olha Skyba, Iryna Mazhak, Svitlana Budnik.
FORECASTING THE POPULATION MORTALITY RATE FROM CARDIOVASCULAR DISEASES AS A CONDITION OF THE ECONOMIC SECURITY OF THE STATE..................................................62-66

Safi K. Yahya, Haiman A. Tawfiq, Yasir Saber.
STIMULATION OF B3-RECEPTOR-INDUCED CENTRAL NEUROGENIC EDEMA AND VITiated ELECTROlyTE HOMEOSTASIS IN EXPERIMENTAL RODENT MODEL........................................67-70

PRODUCTIVITY AND SELENIUM ENRICHMENT OF STEVIA IN HYDROPONIC AND SOIL CULTIVATION SYSTEMS IN THE ARARAT VALLEY.................................................................71-76

Ezzuldin Yaseen Aljunmairy, Ali R. Al-Khatib.
HARDNESS AND ELASTIC MODULUS ASSESSMENT FOR TWO ALIGNER MATERIALS BEFORE AND AFTER THERMOCYCLING: A COMPARATIVE STUDY......................................................77-82

Tchernev G.

Manish Tyagi, Uzma Noor Shah, Geetika Patel M, Varun Toshnival, Rakesh AshokraoBhongade, Pravesh Kumar Sharma.
THE IMPACT OF SLEEP ON PHYSICAL AND MENTAL HEALTH: IMPORTANCE OF HEALTHY SLEEP HABITS........................................89-94

Musayev S.A, Gurbanov E.F.
DYNAMICS OF THE MECHANICAL FUNCTION OF THE LEFT ATRIUM IN PATIENTS WITH ISCHEMIC MITRAL VALVE REGURGITATION.................................................................95-98
INDICATORS OF BONE METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH IMPAIRED BONE MINERAL DENSITY: CHARACTERISTICS, THEIR FEATURES AND DIAGNOSTIC VALUE

Abrahamovych Orest, Abrahamovych Uliana, Chemes Viktoriia, Tsyhanyk Liliya, Mariia Ferko.
Danylo Halytskyi Lviv National Medical University, Ukraine.

Abstract.

**Introduction:** Rheumatoid arthritis (RA) is an autoimmune disease with a chronic inflammatory process that affects bone metabolism and leading to impaired bone mineral density (BMD). Therefore, the determination of laboratory markers of bone metabolism contributes to a better understanding of the pathogenesis of metabolic bone diseases.

**The aim of the study:** To characterize the bone metabolism parameters in rheumatoid arthritis patients with impaired bone mineral density, to find out their features and diagnostic value.

**Materials and methods:** The study included 76 patients randomly stratified by RA status who were treated in the Rheumatology Department of Lviv Regional Clinical Hospital, a municipal non-profit enterprise of Lviv Regional Council, from 2013 to 2019. The goal was achieved by performing three consecutive stages of the study. At the first stage, markers of bone formation and bone resorption were characterized. At the second stage, the peculiarities of these indicators were determined. The third stage was to determine the diagnostic value of the content of the markers of OCN formation, P1NP and resorption marker β-CrossLaps.

**Results:** According to the results of the study at the first stage, it was found that, in RA patients with osteopenia, the serum content of markers of osteoblastic bone function OCN (p=0.000) and P1NP (p=0.035) was significantly lower compared to the healthy individuals of CG, while the content of the marker of bone resorption β-CrossLaps was significantly higher (p=0.021); in RA patients with OP, the serum content of both markers of osteoblastic bone function OCN (p=0.000) and P1NP (p=0.001) is significantly lower, while β-CrossLaps (p>0.050) is only slightly higher compared to healthy CG subjects. According to the results obtained at the second stage of the study, it can be stated that the content of OCN and P1NP in the blood serum is significantly lower in RA patients both with osteopenia and OP compared to RA patients without BMD disorders.

At the third stage of the study, it was found significant relationship between the content of P1NP and belonging to SG1 (AC -0.52). A confirmed relationship was found between the content of OCN and belonging to the group with OP (direct direction of AC 0.57; p=0.017).

**Conclusions:** Bone structure disorders in rheumatoid arthritis patients with osteopenia are characterized by a weakening of bone formation and increased resorption processes; in rheumatoid arthritis patients with osteoporosis, the weakening of osteoblastic bone function is more pronounced compared to rheumatoid arthritis patients with osteopenia. For rheumatoid arthritis patients with unimpaired bone mineral density, the highest diagnostic value is provided by procollagen type I N-terminal propeptide. For rheumatoid arthritis patients with osteoporosis, osteocalcin is a diagnostically valuable marker.

**Key words.** Rheumatoid arthritis, osteoporosis, osteocalcin, procollagen type I N-terminal propeptide, β-CrossLaps, bone mineral density.

**Introduction.**

Rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown etiology with a chronic inflammatory process that usually affects the joints and with increasing severity causes extra-articular lesions [1]. Chronic inflammation in patients with RA affects bone metabolism and disrupts the normal resorption cycle, leading to impaired bone mineral density (BMD) and to osteoporosis [OP] [2]. Changes in bone metabolism occur in patients with RA, which can be manifested by deviations from the reference values of various markers of bone remodeling. From the early stages of RA, bone loss correlates with the activity of inflammation and the patient's condition [3].

Dynamic bone remodeling is ensured by constant bone remodeling. Osteocalcin (OCN), which is a vitamin K-dependent bone non-collagenous protein, a procollagen type I amino-terminal propeptide (P1NP), and alkaline phosphatase (ALP), especially its bone-specific fraction, are responsible for osteoblastic bone function. The osteoclast function of bone is indicated by an isomerized C-terminal telopeptide specific for the degradation of type I collagen in the bone tissue (β-CrossLaps).

Indicators of laboratory markers of bone metabolism contribute to a better understanding of the pathogenesis of metabolic bone diseases, they can provide additional information to the one obtained as a result of instrumental diagnosis of BMD disorders, and they can be useful for the clinician in choosing treatment tactics and evaluating its effectiveness [4].

**The aim of the study.** To characterize the bone metabolism parameters in patients with rheumatoid arthritis with impaired bone mineral density, to find out their features and diagnostic value.

**Materials and methods.**

After signing a voluntary consent to participate in the study, as required by the Helsinki Declaration of Human Rights, the Council of Europe Convention on Human Rights and Biomedicine, patients were randomly enrolled with preliminary stratification by the presence of RA (seropositive (rheumatoid factor, antibodies to citrullinated vimentin, antibodies to cyclic citrulline peptide); polyarthritis (with lesion of small joints of the hands, radiocarpal, shoulder, knee joints; X-ray stage II-III; functional joint failure II); active phase, II level activity;
duration from 1 to 11 years (average 4.63±0.30)) diagnosed in accordance with the Order of the Ministry of Health of Ukraine No. 676 of 12. 10.2006 p. "On approval of protocols for the provision of medical care in the specialty "Rheumatology"" [5] and the criteria of the American College of Rheumatology [6] and the European League Against Rheumatism 2010, 76 patients (64 women (84.21%) in the premenopausal period and 12 men (15.78%) aged 38 to 60 years (mean age at the time of examination of women - 48.67 ± 2.34 years, men - 45.42 ± 2.78)), treated (receiving methylprednisolone according to the scheme at a dose of 4.0 mg/day and a short course during exacerbation up to 24.0 mg/day (on average, 7600.0 ± 260.0 mg per course) and those not receiving medications to treat BMD disorders) in the rheumatology department of the Municipal Non-Profit Enterprise of the Lviv Regional Council "Lviv Regional Clinical Hospital" from 2013 to 2019.

BMD was assessed according to the recommendations of the World Health Organization with the determination of the T-criterion [7], obtained by ultrasound bone densitometry (UBD) of the calcaneus with the SONOST-2000 device (OsteoSysCo., Ltd, Seoul, Korea), which, as proved by Abrahamovich U.O. et al.[9], is not inferior in diagnostic value to the "gold standard" of dual-energy X-ray densitometry. If the standard deviation (SD) was equal or greater than -1.0 SD, we interpreted it as an indicator of normal BMD, if it was less than -1.0 to -2.4 SD, it indicated the presence of osteopenia, if equal or less than -2.5 SD, it indicated the presence of OP. Based on the obtained results, the patients were stratified into the following three groups: 1) 18 patients (15 women (83.33%) and 3 men (16.67%) aged 38 to 52 years) with RA without BMD disorders - comparison group (CPG); 2) 34 patients (31 women (91.18%) and 3 men (8.82%) aged 38 to 54 years) with RA and osteopenia - study group 1 (SG1); 3) 24 patients (18 women (75.00%) and 6 men (25.00%) aged 41 to 53 years) with RA and OP - study group 2 (SG2).

The control group (CG) consisted of 22 practically healthy individuals (18 women (81.81%) and 4 men (18.18%), the average age of women at the time of the examination was 42.95±2.14 years, men - 38.69±2.11 years), who had a T-criterion value of more than -1.0 SD according to the results of the calcaneal DEXA, which indicated the absence of BMD disorders. The content in the serum of bone remodeling indicators, namely markers of bone formation OCN (2.0-22.0 ng/ml), P1NP (women premenopausal - 15.13-58.59 ng/ml; men - 15.00-80.00 ng/ml)) and bone resorption (β-CrossLaps (women. premenopause <0.573 ng/ml; men: 30-50 years <0.584 ng/ml, 50-70 years <0.704 ng/ml)) were studied by immunochemical analysis with electrochemiluminescence detection. The reference indicators were based on the reference values provided by the test system manufacturer in the instructions.

The goal was achieved by performing three consecutive stages of the study. In the first stage, characterizing the markers of bone formation OCN and P1NP, as well as bone resorption β-CrossLaps, these indicators were evaluated in patients with RA with osteopenia of SG1 and in patients with RA with OP of SG2, compared to similar indicators in practically healthy individuals of the CG.

In the second stage, the peculiarities of these indicators were determined in patients with RA with osteopenia of SG1 and in patients with RA with OP of SG2, compared to patients with RA without BMD disorders of the CPG.

The actual material was processed on a personal computer using MS Excel and SPSS software, applying descriptive statistics with the help of point-biserial correlation, Fisher's correlation coefficient, determining the p-value for the correlation coefficient in order to establish the reliability of the strength and direction of the relationship between the two criteria, the difference was considered statistically significant if p< 0.05.

The third stage was to determine the diagnostic value of the content of OCN formation markers, P1NP, and the bone resorption marker β-CrossLaps and there constellations. To achieve this goal, we analyzed the contingency table to calculate the sensitivity, specificity, and diagnostic efficiency (accuracy), as well as association coefficient (AC) among RA patients. Validity and reliability of the defined indicators was determined using sensitivity (a truly positive proportion that reflects the proportion of positive results, correctly identifying a sick subject as a sick subject), specificity (a truly negative proportion that reflects information about the proportion of negative results, correctly identifying a healthy subject as such) and accuracy (the proportion of correctly diagnosed cases based on information about a positive or negative result), AC or contingent coefficient (CC), which characterize the extent to which relationship between qualitative features is close [8]. The relationship between the disease severity and the indicator value was considered as confirmed when the modulo of AC exceeded 0.5 (or 0.3 for CC).

Results.

The results of the first and second stages of the study with information on the average content of bone remodeling markers in patients with RA of CPG, SG1, SG2 and in healthy subjects of the CG are shown in Table 1.

### Table 1. Mean values of bone remodeling markers in patients with rheumatoid arthritis of the comparison group, study groups and control group (M±m; n; p).

<table>
<thead>
<tr>
<th>Groups of patients with RA and healthy control group CG (n)</th>
<th>Markers of bone formation (M±m; p)</th>
<th>Marker of bone Resorption (M±m; p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPG (18 patients)</td>
<td>OCN 24.91±2.75</td>
<td>β-Cross Laps 40.34±4.58</td>
</tr>
<tr>
<td>SG1 (34 patients)</td>
<td>P1NP 17.77±1.21</td>
<td>0.35±0.01</td>
</tr>
<tr>
<td>SG2 (24 patients)</td>
<td>15.38±2.60</td>
<td>0.38±0.02</td>
</tr>
<tr>
<td>CG (22 persons)</td>
<td>20.37±0.76</td>
<td>0.36±0.03</td>
</tr>
</tbody>
</table>

**p-value**

<table>
<thead>
<tr>
<th>p-value</th>
<th>p1=0.008</th>
<th>p2=0.002</th>
<th>p3=0.000</th>
<th>p5=0.005</th>
<th>p6=0.000</th>
<th>p1=0.026</th>
<th>p2&lt;0.005</th>
<th>p5&lt;0.035</th>
<th>p6&lt;0.001</th>
</tr>
</thead>
</table>

**Notes:** p1- significance of differences between SG1 and CPG; p2-significance of differences between SG2 and CPG; p3- significance of differences between CPG and CG; p4- significance of differences between SG1 and SG2; p5- significance of differences between SG1 and CG; p6- significance of differences between SG2 and CG.
Characterizing the markers of bone formation of OCN and P1NP, as well as bone resorption β-CrossLaps, at the first stage of the study, it was found that the content of OCN was significantly lower in patients with RA with osteopenia of SG1 (17.77±1.21 ng/ml) compared to practically healthy individuals of CG (20.37±0.76 ng/ml; p=0.000), the content of P1NP was significantly lower in RA patients with osteopenia of SG1 (30.16±2.17 ng/ml) compared to practically healthy individuals of the CG (37.40±2.37 ng/ml; p=0.035), and the content of β-CrossLaps was significantly higher in RA patients with SG1 osteopenia (0.38±0.02 ng/mL) compared to practically healthy CG subjects (0.31±0.01 ng/mL; p=0.021).

In patients with RA with OP SG2, the index of OCN was significantly lower (15.38±2.60 ng/ml) compared to practically healthy individuals of the CG (20.37±0.76 ng/ml; p=0.000), the content of P1NP was significantly lower compared to patients with RA with OP SG2 (26.58±2.03 ng/ml) compared to practically healthy individuals of the CG (37.40±2.37 ng/ml; p=0.001), the content of β-CrossLaps was not significantly higher in RA patients with DG2 OP (0.36±0.03 ng/ml) compared to practically healthy CG subjects (0.31±0.01 ng/ml).

According to the results of the study, at the first stage, it can be stated that in patients with RA with osteopenia, the serum content of markers of osteoblastic bone function OCN and P1NP was significantly lower compared to healthy CG subjects, while the content of the bone resorption marker β-CrossLaps was significantly higher; in patients with RA with OP, the serum levels of both markers of osteoblastic bone function OCN and P1NP are significantly lower, while β-CrossLaps is only slightly higher compared to healthy CG subjects.

The second stage of the study consisted in defining the peculiarities of the indicators of OCN and P1NP bone formation markers, and β-CrossLaps bone resorption markers. It was found that OCN content was significantly lower in RA patients with osteopenia of SG1 (17.77±1.21 ng/ml) compared to RA patients without impaired BMD of CPG (24.91±2.75 ng/ml; p=0.008 ng/ml), P1NP indicator was significantly lower in RA patients with osteopenia of SG1 (30.16±2.17 ng/ml), compared to RA patients without impaired BMD of CPG, (40.34±4.58 ng/ml; p=0.026), and the content of β-CrossLaps did not show significant difference between the values in RA patients with osteopenia of SG1 (0.38±0.02 ng/ml), compared to RA patients without impaired BMD of CPG (0.35±0.01 ng/ml; p>0.050).

In RA patients with OP of SG2, it was found that the index of OCN was significantly lower (15.38±2.60 ng/ml) compared to RA patients without impaired BMD of CPG (24.91±2.75 ng/ml; p=0.002), P1NP indicator was significantly lower in RA patients with OP of SG2 (26.58±2.0 ng/ml), compared to RA patients without impaired BMD of CPG (40.34±4.58 ng/ml; p<0.005), and β-CrossLaps content did not show a significant difference between the values in RA patients with OP of SG2 (0.36±0.003 ng/ml), compared to RA patients without impaired BMD of CPG (0.35±0.01 ng/ml; p>0.050).

Comparing OCN and P1NP markers of bone formation, as well as β-CrossLaps bone resorption in RA patients with osteopenia of SG1 and with OP of SG2, no significant difference was found between them. According to the results of the second stage of the study, it can be argued that OCN and P1NP content in the blood serum is significantly lower in RA patients both with osteopenia and OP, compared to RA patients without BMD disorders. β-CrossLaps content did not show a significant difference between the values in RA patients with osteopenia of SG1 and with OP of SG2.

The results of the third stage of the study, which consisted in the determination of sensitivity, specificity, and accuracy of bone remodeling markers in RA patients with BMD disorders, are shown in Table 2.

The sensitivity in RA patients with osteopenia of SG1 compared with RA patients without BMD disorders (CPG) is 26.64%, specificity - 72.22%, accuracy - 42.31%. There was no confirmed relationship between the content of OCN and belonging to SG1 (inverse direction of AC was 0.03, p>0.050). The sensitivity of P1NP in RA patients with osteopenia of SG1 compared with RA patients without BMD disorders (CPG) is 5.88%, specificity - 83.33%, accuracy - 32.69%. A significant relationship was found between the content of P1NPs and belonging to SG1 group (inverse direction of AC -0.52).

The sensitivity of β-CrossLaps content in RA patients with osteopenia of SG1 compared with RA patients without BMD disorders (CPG) is 8.23 %, specificity - 100.00 %, accuracy - 40.38 %. No significant relationship was found between the content of β-CrossLaps and belonging to SG1 (inverse direction of AC - 0.18, p>0.050).

The analysis of the constellations of laboratory parameters revealed the constellation of P1NP and OCN (inverse direction of AC -0.73), which indicates that the constellation of these parameters is not typical for RA patients with osteopenia, but is typical for RA patients without BMD disorders (CPG).

OP is 3.38 times more common in RA patients if the content of OCN is below the reference values compared to RA patients without BMD (CPG). The sensitivity of OCN in RA patients of SG2 compared with RA patients without BMD disorders was 56.52 %, specificity - 72.22 %, accuracy - 63.41 %. A confirmed direct correlation was found between the content of OCN and belonging to the group with OP (AC 0.54; p=0.048). The sensitivity of P1NP in RA patients with OP of SG2 is 0.00 %, specificity - 83.33 %, accuracy - 36.58 %. A significant inverse relationship was found between the P1NP content and belonging to SG2 (CC - 0.31). The sensitivity of the β-CrossLaps content in SG2 was 8.69 %, specificity - 100.00 %, accuracy - 48.78 %. No significant relationship was found between the content of β-CrossLaps and belonging to SG2 (CC 0.2).

Analyzing the constellations of laboratory parameters, a constellation of P1NP and OCN, a significant relationship was found (inverse direction of CC -0.31), which indicates that the constellation of these parameters is not typical for RA patients with OP, but it is typical for RA patients without impaired BMD of CPG.

OP is 3.60 times more common in RA patients of SG2 compared with RA patients with osteopenia of SG1, if the OCN content is lower than the reference values. The sensitivity of OCN in RA patients with OP of SG2 compared with RA patients with osteopenia (SG1) is 56.52 %, specificity - 73.52 %, accuracy - 66.67 %. A confirmed relationship was found
### Table 2. The results of comparison of the diagnostic value of bone remodeling parameters in RA patients without (CG) and with impairments (SG1, SG2) of BMD (% sensitivity; % specificity; % accuracy; AC (in units); CC (in units)).

<table>
<thead>
<tr>
<th>Groups of RA patients</th>
<th>Indicators of bone remodeling</th>
<th>Indicators of diagnostic value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Sensitivity, %.</td>
</tr>
<tr>
<td>SG1</td>
<td>OCN</td>
<td>26,64</td>
</tr>
<tr>
<td></td>
<td>P1NP</td>
<td>5,88</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps</td>
<td>8,23</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps +OCN</td>
<td>0,00</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps + P1NP</td>
<td>0,00</td>
</tr>
<tr>
<td></td>
<td>P1NP + OCN</td>
<td>2,94</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps + P1NP + OCN</td>
<td>0,00</td>
</tr>
<tr>
<td>SG2</td>
<td>OCN</td>
<td>56,52</td>
</tr>
<tr>
<td></td>
<td>P1NP</td>
<td>0,00</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps</td>
<td>8,69</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps +OCN</td>
<td>0,00</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps + P1NP</td>
<td>0,00</td>
</tr>
<tr>
<td></td>
<td>P1NP + OCN</td>
<td>0,00</td>
</tr>
<tr>
<td></td>
<td>β-CrossLaps + P1NP + OCN</td>
<td>0,00</td>
</tr>
</tbody>
</table>

Notes: * - statistically significant relationship between indicators and group membership (AC 0.5 or more), ^ - statistically significant relationship between indicators and group membership (AC 0.3 or more), # - statistically significant difference between the frequency of cases in the groups (p < 0.050).

between the content of OCN and belonging to the group with OP (direct direction of AC 0.57; p<0.017). The sensitivity of P1NP in RA patients with OP of SG2 is 0.00 %, specificity - 94.11 %, accuracy - 56.11 %. No significant relationship was found between P1NP content and belonging to SG2 (reverse direction of CC - 0.15). The sensitivity of β-CrossLaps in RA patients with osteopenia of SG2 compared with RA patients with osteopenia of SG1 was 8.69 %, specificity - 91.17 %, accuracy - 57.89 %. No significant relationship was found between the content of β-CrossLaps and belonging to SG2 (reverse direction of CC -0.008). When analyzing the constellations of laboratory parameters in RA patients with OP, we did not find statistically significant changes.

### Conclusion.

1. Bone structure disorders in patients with RA with osteopenia are characterized with a weakening of bone formation and increased resorption processes; in patients with RA with OP, the weakening of osteoblastic bone function is more pronounced compared to patients with RA with osteopenia, and only a slight increase in bone resorption processes.

2. We did not find any particular differences in the weakening of bone formation and resorption in patients with RA with osteopenia and OP, assessed by the results of determining the serum markers of osteoblastic OCN and P1NP, as well as osteoclastic β-CrossLaps functions.

3. For rheumatoid arthritis patients with intact bone mineral density, the highest diagnostic value is provided by an increase in the amino-terminal procollagen type I propeptide or a constellation of a decrease in osteocalcin and an increase in the amino-terminal procollagen type I propeptide.

4. As a result of the study of the diagnostic value of single markers of bone formation osteocalcin and amino-terminal procollagen type I propeptide, as well as bone resorption of carboxy-terminal telopeptide of type I collagen, and their constellations in patients with rheumatoid arthritis with osteopenia, we did not find statistically significant changes in sensitivity, specificity, and accuracy.

5. For osteoporosis in patients with rheumatoid arthritis, a decrease in a single indicator of osteocalcin is a diagnostically valuable marker; we did not find statistically significant changes in sensitivity, specificity, and accuracy of constellations of bone formation indicators of osteocalcin and amino-terminal procollagen type I propeptide and bone resorption of carboxy-terminal telopeptide of type I collagen.

### REFERENCES


5. Order of the Ministry of Health of Ukraine № 676 dated 12.10.2006 On approval of medical care protocols in the specialty "Rheumatology" (Ukrainian).


ძვლის მეტაბოლიზმის მაჩვენებლები რევმატოიდული ართრიტის მქონე პაციენტებში ძვლის ქსოვილის მინერალური სიმკვრივის დარღვევით: მათი მახასიათებლები, თავისებურებები და დიაგნოსტიკური ღირებულები.

Abrahamovych Orest, Abrahamovych Uliana, Chemes Viktoriia, Tsyhanyk Liliya, Mariia Ferko

Danylo Halyskyi Lviv National Medical University, Lviv, Ukraine.

საკვანძო სიტყვები:  რევმატოიდული ართრიტი, ოსტეოპოროზი, ოსტეოკალცინი, I ტიპის პროკოლაგენის N-ტერმინალური პროპეპტიდი, β-CrossLaps, ძვლოვანი ქსოვილის მინერალური სიმკვრივი.
Вступление. Ревматоидный артрит (РА) — аутоиммунное заболевание с хроническим воспалительным процессом, влияющим на костный метаболизм и приводящим к нарушению минеральной плотности костной ткани (МПКТ). Поэтому определение лабораторных маркеров костного метаболизма способствует лучшему пониманию патогенеза метаболических заболеваний костей.

Цель. Охарактеризовать показатели костного метаболизма у больных ревматоидным артритом с нарушением минеральной плотности костной ткани, выяснить их особенности и диагностическую ценность.

Материалы и методы. В исследование рандомизированным способом с предварительной стратификацией по наличию RA было включено 76 больных, которые лечились в ревматологическом отделе Коммунального некоммерческого предприятия Львовского областного совета «Львовская областная клиническая больница» в период между 2013 и 2020 годами. Достижение цели реализовано выполнением трех последовательных этапов исследования. На первом этапе характеризуя маркеры формирования костей, а также резорбции кости. На втором этапе выяснили особенности этих показателей. Третий этап заключался в определении диагностической ценности содержания маркеров формирования ОК, P1NP и маркера резорбции β-CrossLaps.

Результаты. Согласно полученным результатам исследования на первом этапе было обнаружено, что у больных RA с остеопенией содержание в сыворотке крови обоих маркеров остеобластной функции костей ОК (р<0.000) и P1NP (р=0.035) было достоверно меньше по сравнению со здоровыми лицами КГ, в то время как содержание маркера резорбции кости β-CrossLaps было достоверно больше (р=0.021); у больных RA с ОП содержание в сыворотке крови обоих маркеров остеобластной функции костей ОК (р=0.000) и P1NP (р=0.001) достоверно меньше, в то время как β-CrossLaps (р>0.050) - лишь несколько больше, сравнительно со здоровыми лицами КГ. Согласно полученным на втором этапе результатам исследования можно утверждать, что содержание ОК и P1NP в сыворотке крови достоверно меньше у больных RA с остеопенией, так и с ОП, по сравнению с больными RA без нарушения МПКТ. На третьем этапе исследования было обнаружено, между содержанием P1NP и принадлежностью к группе остеопении обнаружена обратная достоверная связь (КА -0.52). Между содержимым ОК и принадлежностью к группе ОП обнаружена подтвержденная связь (прямое направление КА 0.57; р=0.017).

Выводы. Для нарушения структуры костей у больных ревматоидным артритом с остеопенией характерно ослабление процессов образования кости у них и усиление процессов резорбции; у больных ревматоидным артритом с остеопорозом ослабление остеобластной функции кости более выражено, по сравнению с больными ревматоидным артритом с остеопенией. Особых отличий ослабления процессов формирования и резорбции костей у больных ревматоидным артритом с остеопенией и остеопорозом нами не обнаружено. Для больных ревматоидным артритом с ненарушенной минеральной плотностью костной ткани наибольшую диагностическую ценность имеет показатель N-терминальный пропептид проколлагена I типа. Для больных ревматоидным артритом c остеопорозом диагностически ценным маркером является остеокальцин.

Ключевые слова. Ревматоидный артрит, остеопороз, остеокальцин, N-терминальный пропептид проколлагена I типа, β-CrossLaps, минеральная плотность костной ткани.